#USA #Bridgewater #Hamamatsu #Sirona Dx #Spatial Proteomics

Strategic Partnership Launched to Improve Technology Access in Spatial Proteomics

In a significant move towards advancing the field of spatial proteomics, Hamamatsu Photonics, a prominent player in whole slide imaging and spatial proteomics solutions, has officially announced a strategic partnership with Sirona Dx (SDX). This collaboration aims to enhance the Technology Access Program (TAP), designed to simplify the evaluation process for researchers looking to implement spatial biology solutions.

Addressing the Challenges in Technology Evaluation

As the demand for solutions in spatial proteomics climbs, researchers face numerous hurdles in assessing new technologies, primarily due to complexities tied to sample preparation, staining, and imaging processes. In response, Hamamatsu has meticulously developed the Technology Access Program. This initiative allows potential users to assess MoxiePlex Systems without navigating the often cumbersome workflows associated with staining, panel development, and bioinformatics analysis.

What the Partnership Offers

The collaboration between Hamamatsu and SDX not only facilitates seamless access to innovative technology but also impacts the industry's landscape significantly. Here are a few benefits it brings:

• - Seamless Technology Access: Researchers can now evaluate cutting-edge spatial proteomics technology within a GCLP/CLIA accredited laboratory, alleviating concerns over sample preparation and imaging workflows.
• - Flexibility and Scalability: The partnership supports a broad spectrum of needs, catering to various sectors including research, clinical applications, and pharmaceuticals.

Executive Insights

James Butler, Vice President of Marketing at Hamamatsu Corporation, expressed that this partnership amplifies their capability to support customers through the evaluation and adoption of spatial proteomics solutions. He stated, "By merging our state-of-the-art imaging technology with SDX's leading edge expertise in spatial biology and technology validation, we are eradicating the operational hurdles researchers frequently encounter."

Andrew Brown, Chief Commercial Officer at Sirona Dx, conveyed excitement about the new partnership, emphasizing the intention behind the MoxiePlex technology to bridge the gap between innovative spatial imaging and clinical decision-makers. He articulated that the design of MoxiePlex prioritizes lower plex fluorescence, ensuring maximum clinical utility alongside speed, precision, and scalability.

About the Companies

Hamamatsu Photonics

Hamamatsu Photonics K.K. is well-regarded for its extensive range of photonics devices that include optical sensors, light sources and high-performance cameras. Their products, particularly whole slide imaging systems, are renowned for their precision and reliability. For further details, you can visit their website at www.hamamatsu.com.

Sirona Dx (SDX)

On the other hand, Sirona Dx stands as a leading technical contract research organization specializing in single-cell multi-omics and spatial biology services. They support the optimization, design, and bioinformatics analysis of complex, multi-analyte assays within a regulatory framework that advances biomarker discovery and accelerates therapeutic development. To learn more, check out their website at www.sironadx.com.

Conclusion

As the collaboration unfolds, researchers and clinicians can look forward to a more streamlined and efficient path toward adopting spatial proteomics technologies. Both companies are poised to make impactful contributions within the field, accelerating advancements in research and clinical applications. This partnership not only demonstrates their commitment to innovation but also reinforces their roles as leaders in their respective areas of expertise.